Editor's Corner

Those of you interested in economic development should tune in to our discussion on that topic coming up on Thursday at 1:30 p.m. EST. We have Mike Luger, an expert on biotech economic development and currently head of the Manchester Business School, on board along with Biocom CEO Joe Panetta and Debbie Hart, president of the Biotechnology Council of New Jersey. I'll be there, too, discussing FierceBiotech's lineup of the most intriguing economic development programs appearing around the world. Economic development groups have been blueprinting some very ambitious programs to encourage the growth of biotechnology. These programs could have a direct effect on your company. We'll examine which approaches are gaining the most attention and which have the best chance of success. It's interactive, so come prepared to ask questions. Check out this website to sign up and get all the log-in info. - John

Suggested Articles

Merck’s TIGIT-blocking prospect and PD-1 med Keytruda shrank tumors in 29% of lung cancer patients who had never tried a checkpoint inhibitor.

Merck's HIF-2α inhibitor, picked up in its $1 billion Peloton buyout, shrank kidney tumors in 36% of patients and showed promise in other tumors, too.

Amunix reported that a single dose of its lead T-cell engager caused caused large HER2-positive tumors to shrink in mice.